Kronos Bio, Inc. announced that it will present positive preliminary data from the phase 1 dose escalation portion of the ongoing phase 1/2 KB-0742 study at the Connective Tissue Oncology Society annual meeting being held November 1-4, 2023, in Dublin, Ireland. The presentation will include clinical data that was first presented at the AACR-NCI-EORTC International Conference on October 13, 2023, in Boston, Mass in the context of pre-clinical models that provide a better understanding of the observed anti-tumor activity. Oral Presentation information: Session Title: Session 4: Medical and Pediatric Oncology and Trials.

Presentation Title: A first in-human study of CDK9 inhibitor KB-0742 demonstrates preliminary evidence of clinical activity in transcriptionally addicted sarcomas. Presenter: Brian Van Tine, M.D., of Washington University School of Medicine in St. Louis.

Abstract #: 1569811. Date and Time: Thursday November 2, 2023, from 4:00 PM - 5:30 PM IST. To read the press release on the data presented at the AACR-NCI-EORTC International Conference in Boston, Mass.